Yahoo
NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

82.29 +2.36 (+2.95%)
At close: October 30 at 4:00:01 PM EDT
83.50 +1.21 (+1.47%)
After hours: October 30 at 4:35:29 PM EDT
Trade DexCom on Coinbase
DXCM Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for DXCM

What's happening with DXCM?

37m ago
Powered by Yahoo Scout

DexCom reported a strong third quarter, beating analyst expectations and raising its 2026 revenue outlook to $5.20 billion–$5.25 billion. Growth remains strongest in the United States, while improved margins, the G7 15 Day rollout, broader coverage prospects, and buybacks shape the outlook.

Powered by Yahoo Scout
  • Previous Close 79.93
  • Open 81.52
  • Bid 77.21 x 200
  • Ask 89.80 x 200
  • Day's Range 79.79 - 85.25
  • 52 Week Range 54.11 - 92.59
  • Volume 8,637,191
  • Avg. Volume 4,621,084
  • Market Cap (intraday) 31.053B
  • Beta (5Y Monthly) 1.48
  • PE Ratio (TTM) 31.65
  • EPS (TTM) 2.60
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 96.96
  • Morningstar Rating Rating available with Stock Picks access

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

www.dexcom.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DXCM
23.99%
S&P 500 (^GSPC)
10.73%

1-Year Return

DXCM
20.66%
S&P 500 (^GSPC)
11.11%

3-Year Return

DXCM
3.09%
S&P 500 (^GSPC)
81.91%

5-Year Return

DXCM
47.18%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.34B
Earnings 275.1M
Profit Margin 20.46%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
17.0%
18.0%
19.0%
20.0%
21.0%

Analyst Insights

View More

Analyst Price Targets

79.00
96.96 Average
82.29 Current
120.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/31/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 102 -> 107

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.12%

  • Return on Assets (ttm)

    10.33%

  • Return on Equity (ttm)

    38.49%

  • Revenue (ttm)

    4.97B

  • Net Income Avi to Common (ttm)

    999.7M

  • Diluted EPS (ttm)

    2.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.95B

  • Total Debt/Equity (mrq)

    53.35%

  • Levered Free Cash Flow (ttm)

    1.02B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: